Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Diels

Showing results (301-310 of 351) with videos related to

Pageof 36
Sort By:
Cancers|November 25, 2023
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating <i>EGFR</i> Exon 20 Insertion MutationsPetros Christopoulos, Nicolas Girard, Claudia Proto, et al.
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|January 13, 2025
Egg allergen-specific T-cell and cytokine responses in healthy and egg-allergic children naturally tolerating baked eggLiselot De Vlieger, Lisa Nuyttens, Cheyenne Keppens, et al.
Scientific Reports|November 8, 2016
Sustained synchronized neuronal network activity in a human astrocyte co-culture systemJacobine Kuijlaars, Tutu Oyelami, Annick Diels, et al.
Hemasphere|December 8, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical PracticeMichel Delforge, Marie-Christiane Vekemans, Julien Depaus, et al.
Cancer Treatment and Research Communications|July 21, 2024
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS studyNicolas Girard, Keunchil Park, Se-Hoon Lee, et al.
Current Medical Research and Opinion|October 22, 2022
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Leukemia & Lymphoma|January 4, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS studyPaula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, et al.
Scientific Reports|August 16, 2019
Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistanceGabriela Torrea, Kamela C S Ng, Armand Van Deun, et al.
Pageof 36

Showing results (301-310 of 351) with videos related to

Sort By:
Pageof 36
Cancers|November 25, 2023
Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating <i>EGFR</i> Exon 20 Insertion MutationsPetros Christopoulos, Nicolas Girard, Claudia Proto, et al.
Clinical Drug Investigation|November 25, 2021
Comparative Efficacy of Ciltacabtagene Autoleucel in CARTITUDE-1 vs Physician's Choice of Therapy in the Long-Term Follow-Up of POLLUX, CASTOR, and EQUULEUS Clinical Trials for the Treatment of Patients with Relapsed or Refractory Multiple MyelomaKatja Weisel, Thomas Martin, Amrita Krishnan, et al.
Cancers|December 10, 2021
Adjusted Comparison of Outcomes between Patients from CARTITUDE-1 versus Multiple Myeloma Patients with Prior Exposure to PI, Imid and Anti-CD-38 from a German RegistryMaximilian Merz, Hartmut Goldschmidt, Parameswaran Hari, et al.
Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology|January 13, 2025
Egg allergen-specific T-cell and cytokine responses in healthy and egg-allergic children naturally tolerating baked eggLiselot De Vlieger, Lisa Nuyttens, Cheyenne Keppens, et al.
Scientific Reports|November 8, 2016
Sustained synchronized neuronal network activity in a human astrocyte co-culture systemJacobine Kuijlaars, Tutu Oyelami, Annick Diels, et al.
Hemasphere|December 8, 2022
Ciltacabtagene Autoleucel for Patients With Triple-class Exposed Multiple Myeloma: Adjusted Comparison of CARTITUDE-1 Patient Outcomes Versus Real-world Clinical PracticeMichel Delforge, Marie-Christiane Vekemans, Julien Depaus, et al.
Cancer Treatment and Research Communications|July 21, 2024
A brief report on stable disease among amivantamab-treated patients with post-platinum epidermal growth factor receptor exon 20 insertion-mutated non-small cell lung cancer: A response-based analysis from the CHRYSALIS studyNicolas Girard, Keunchil Park, Se-Hoon Lee, et al.
Current Medical Research and Opinion|October 22, 2022
Updated results from a matching-adjusted indirect comparison of efficacy outcomes for ciltacabtagene autoleucel in CARTITUDE-1 versus idecabtagene vicleucel in KarMMa for the treatment of patients with relapsed or refractory multiple myelomaTom Martin, Saad Z Usmani, Jordan M Schecter, et al.
Leukemia & Lymphoma|January 4, 2018
Improvement of fatigue, physical functioning, and well-being among patients with severe impairment at baseline receiving ibrutinib in combination with bendamustine and rituximab for relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma in the HELIOS studyPaula Cramer, Graeme Fraser, Rodrigo Santucci-Silva, et al.
Scientific Reports|August 16, 2019
Variable ability of rapid tests to detect Mycobacterium tuberculosis rpoB mutations conferring phenotypically occult rifampicin resistanceGabriela Torrea, Kamela C S Ng, Armand Van Deun, et al.
Pageof 36